Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus OXYLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus OXYLONE.
COR-OTICIN vs OXYLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Corticosteroid that binds to glucocorticoid receptors, modulating transcription of anti-inflammatory proteins and suppressing immune response.
1-2 drops in each affected ear twice daily for 7 days.
Apply topically to affected area twice daily.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: 1.5-2.5 hours. Clinical context: Short half-life necessitates multiple daily dosing for sustained anti-inflammatory effect; accumulation minimal with repeated dosing.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: 70-90% (as metabolites, mainly 6β-hydroxycortisol and other conjugates); Biliary/fecal: <10%; Unchanged drug: <5% in urine.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid